---
title: "Sichuan Kelun-Biotech Receives NMPA Approval for Sacituzumab Tirumotecan in Advanced HR+/HER2- Breast Cancer"
description: "Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. has received approval from the National Medical Products Administration (NMPA) in China for its antibody-drug conjugate, sacituzumab tirumotecan (sac-"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/275096325.md"
published_at: "2026-02-06T08:33:51.000Z"
---

# Sichuan Kelun-Biotech Receives NMPA Approval for Sacituzumab Tirumotecan in Advanced HR+/HER2- Breast Cancer

> Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. has received approval from the National Medical Products Administration (NMPA) in China for its antibody-drug conjugate, sacituzumab tirumotecan (sac-TMT), to treat adult patients with unresectable or metastatic HR+/HER2- breast cancer who have undergone at least one prior systemic therapy. This is the fourth approved indication for sac-TMT by the NMPA.

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. announced that its TROP2-directed antibody-drug conjugate (ADC), sacituzumab tirumotecan (sac-TMT, also known as SKB264/MK-2870), has been approved by the National Medical Products Administration (NMPA) of China for a new indication. The approval covers the treatment of adult patients with unresectable or metastatic hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer who have received at least one prior systemic therapy. This marks the fourth approved indication for sac-TMT by the NMPA. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260206-12017668), on February 06, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [588250.CN - Penghua SSE STAR Biology and Medicine ETF](https://longbridge.com/en/quote/588250.CN.md)
- [159316.CN - E Fund Hang Seng SCHK Innovative Drug ETF](https://longbridge.com/en/quote/159316.CN.md)
- [159102.CN - Huaan Hang Seng Biotech ETF](https://longbridge.com/en/quote/159102.CN.md)
- [512010.CN - E Fund CSI 300 Health Care ETF](https://longbridge.com/en/quote/512010.CN.md)
- [159849.CN - China Merchants CSI Biotechnology Theme ETF](https://longbridge.com/en/quote/159849.CN.md)
- [159992.CN - Yinhua CSI Innovative Drugs Industry ETF](https://longbridge.com/en/quote/159992.CN.md)
- [512290.CN - Guotai CSI Bio-medicine ETF](https://longbridge.com/en/quote/512290.CN.md)
- [516820.CN - Ping An CSI Medicine and Medical Device Innovation ETF](https://longbridge.com/en/quote/516820.CN.md)
- [06990.HK - SKB BIO-B](https://longbridge.com/en/quote/06990.HK.md)
- [159837.CN - E Fund CSI Biotechnology Theme ETF](https://longbridge.com/en/quote/159837.CN.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 石四藥 (2005) 發盈警料去年盈利倒退 45 至 60% | 石四藥集團發盈警，預期截至去年底止年度股東應佔溢利按年下跌 45 至 60%；2024 年度錄得股東應佔溢利 10.61 億港元。 | [Link](https://longbridge.com/en/news/276431030.md) |
| 基石藥業-B 的肺癌藥物 Sugemalimab 獲得英國第二次批准 | 藥明康德（CStone Pharmaceuticals）已獲得英國批准，將其肺癌藥物 sugemalimab 作為單藥治療用於不可切除的 III 期非小細胞肺癌成人患者。這標誌着該藥物在英國的第二個適應症，得益於 III 期 GEMSTON | [Link](https://longbridge.com/en/news/276549711.md) |
| 埃隆·馬斯克的 Neuralink 在中國激發了腦機接口技術的競賽 | Neuralink，由埃隆·馬斯克創立，正在推動中國腦機接口（BCI）發展的熱潮，像 NeuroXess 這樣的初創公司迅速進入人體試驗階段。NeuroXess 於 2021 年成立，已經在患者身上測試植入物。中國政府已將 BCI 列為戰略 | [Link](https://longbridge.com/en/news/276460367.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.